Platelets Archives - EMEA

This site provides INTERCEPT product information for International audiences .

Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

by jaycornell | May 6, 2025

Dr. Richard J. Benjamin, MBChB, PhD, FRCPath Cerus Corporation Concord, California, USA

Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components

Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components

by jaycornell | May 6, 2025

Stanford Blood Center California, United States

Overview of the variability in platelet production processes and applied safety measures

Overview of the variability in platelet production processes and applied safety measures

by jaycornell | May 6, 2025

Dr. Mohammad R. Abedi, MD, PhD Örebro University Hospital Stockholm, Sweden

Case study: impact of pathogen inactivation on outdating rates and supply continuity

Case study: impact of pathogen inactivation on outdating rates and supply continuity

by jaycornell | May 6, 2025

Ms. Ragna Landrö, BSc The Blood Bank The National University Hospital of Iceland Reykjavík, Iceland

Case study: enabling double dose methodology on Reveos through pathogen inactivation

Case study: enabling double dose methodology on Reveos through pathogen inactivation

by jaycornell | May 6, 2025

Ms. Eleonore Tennby Cerus Europe B.V. Amersfoort, the Netherlands

« Older Entries